MAR 31, 2017 2:29 PM PDT

New Multiple Sclerosis Drug Wins FDA Approval

WRITTEN BY: Xuan Pham

The FDA recently approved the first drug for the treatment of relapsing forms of multiple sclerosis (MS). The announcement marks a significant achievement, which is expected to help the 400,000 MS patients in the US.

Multiple sclerosis is described as a demyelinating disease whereby the body’s immune system mistakenly attacks the myelin sheath covers in the brain and spinal cord. This disrupts the electrical signal traveling from the brain to the body, and leads to physical and neurologic disabilities. The progressive form of MS causes patients to slowly deteriorate over time, while the relapsing form causes patients to go through bouts of symptoms and recovery. There is no cure for either form of MS.

“Multiple sclerosis can have a profound impact on a person’s life,” said Billy Dunn, the director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “This therapy not only provides another treatment option for those with relapsing MS, but for the first time provides an approved therapy for those with primary progressive MS.”

The drug is known on the market as Ocrevus (ocrelizumab), and it works by weakening the immune system. In particular, IV infusions of Ocrevus prevent the B cells from attacking the protective myelin covers.

Tested in patients with both forms of MS (the progressive form and the relapsing remitting form), Ocrevus seems to stop the inflammation process in the brain. This results in less fatigue and muscle weakness. Vision seems to also be improved. Furthermore, scans show significantly less brain loss with the help of ocrelizumab.

"The drug is so much more effective at shutting down inflammation," said David Hafler, an MS expert from the Yale School of Medicine.

Side effects associated with Ocrevus include infusion-related reactions, such as skin irritation, flushing, shortness of breath, and nausea. In addition, upper respiratory tract infections were among the most common side effect seen with the drug in both forms of MS.

Patients eager to be treated with Ocrevus will have to wait just a few more weeks. Furthermore, they should also be aware that this drug comes with a hefty price tag of $65,000 per year. Though the cost is substantial, it is reportedly on par with approved drugs for the other forms of MS.

Additional sources: CNN

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 21, 2020
Cancer
Can Excess Fructose Cause Liver Cancer?
OCT 21, 2020
Can Excess Fructose Cause Liver Cancer?
Hepatocellular carcinoma, aka liver cancer, is an ever-increasing issue in the western world. While the lion’s sha ...
NOV 12, 2020
Clinical & Molecular DX
Study Shows 1 in 5 COVID Tests Are False Positives
NOV 12, 2020
Study Shows 1 in 5 COVID Tests Are False Positives
  A study published in The BMJ has brought to light that the rapid finger-prick COVID-19 test may not be quite as r ...
DEC 03, 2020
Neuroscience
Scientists Invent Noninvasive Microscope to Observe Neurons
DEC 03, 2020
Scientists Invent Noninvasive Microscope to Observe Neurons
To obtain high-resolution images of the brain, researchers usually need to reduce the thickness of the skull or cut into ...
JAN 08, 2021
Neuroscience
Can We Identify Alzheimer's from Routine Eye Exams?
JAN 08, 2021
Can We Identify Alzheimer's from Routine Eye Exams?
As people with diabetes age, they are more likely than those without the condition to develop cognitive disorders such a ...
FEB 04, 2021
Clinical & Molecular DX
Neurological and Psychiatric Aftershocks of the Pandemic
FEB 04, 2021
Neurological and Psychiatric Aftershocks of the Pandemic
One in eight COVID-19 survivors have received a diagnosis of a neurological or psychiatric condition in the year followi ...
FEB 25, 2021
Clinical & Molecular DX
A Better Way to Triage COVID Patients
FEB 25, 2021
A Better Way to Triage COVID Patients
Australian researchers have developed a COVID-19 triaging tool that serves as a crystal ball for healthcare workers. Onc ...
Loading Comments...